CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Hydroxychloroquine Sulfate and Folic AcidWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (4)

Name (Synonyms) Correlation
drug566 Normal Saline Infusion + Maximal intensive care Wiki 1.00
drug387 Hydroxychloroquine Sulfate and Azithromycin Wiki 1.00
drug61 Ascorbic Acid and Folic Acid Wiki 1.00
drug78 Aviptadil by intravenous infusion + maximal intensive care Wiki 1.00

Correlated MeSH Terms (7)

Name (Synonyms) Correlation
D055370 Lung Injury NIH 0.32
D055371 Acute Lung Injury NIH 0.16
D013577 Syndrome NIH 0.15
D012127 Respiratory Distress Syndrome, Newborn NIH 0.15
D012128 Respiratory Distress Syndrome, Adult NIH 0.13
D045169 Severe Acute Respiratory Syndrome NIH 0.07
D018352 Coronavirus Infections NIH 0.06

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 Efficacy of Novel Agents for Treatment of SARS-CoV-2 Infection Among High-Risk Outpatient Adults: An Adaptive Randomized Platform Trial

This is a randomized trial for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in high-risk adults not requiring hospital admission.The overarching goal of this study is to assess the effectiveness of interventions on the incidence of lower respiratory tract infection (LRTI) progression among high-risk adult outpatients with SARS-CoV-2 infection to inform public health control strategies.

NCT04354428 COVID-19 SARS-CoV-2 Drug: Ascorbic Acid and Folic Acid Drug: Hydroxychloroquine Sulfate and Folic Acid Drug: Hydroxychloroquine Sulfate and Azithromycin

Primary Outcomes

Description: Resting blood oxygen saturation (SpO2<93%) level sustained for 2 readings 2 hours apart and presence of subjective dyspnea or cough

Measure: Lower respiratory tract infection (LRTI) rates

Time: 28 days from enrolment

Description: Cumulative incidence of hospitalization or mortality

Measure: Incidence of hospitalization or mortality

Time: Day 28 after enrolment

Description: Time to clearance of nasal SARS-CoV-2, defined as 2 consecutive negative swabs

Measure: Change in upper respiratory viral shedding

Time: Day 1 through Day 14 after enrolment

Secondary Outcomes

Description: Serious adverse events (including death and hospitalization) and adverse events resulting in treatment discontinuation

Measure: Rate of participant-reported adverse events

Time: 28 days from enrolment

No related HPO nodes (Using clinical trials)